Please use this identifier to cite or link to this item:
|Title:||Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer|
Moreno Guillén, Estefanía
Caffarel, María M.
Homar Ruano, Patricia C.
McCormick, Peter J.
Canela Campos, Enric I.
Sánchez Mora, Cristina
|Keywords:||Càncer de mama|
|Publisher:||National Academy of Sciences|
|Abstract:||There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2-CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer|
|Note:||Reproducció del document publicat a: https://doi.org/10.1073/pnas.1815034116|
|It is part of:||Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 116, num. 9, p. 3863-3872|
|Appears in Collections:||Articles publicats en revistes (Bioquímica i Biomedicina Molecular)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.